Agilex Biolabs, Australia's largest specialist bioanalytical laboratory for clinical trials, and Endpoints News launched
a new webinar "How Easy is it to Move Your Trials to Australia" at BIO Taiwan 2020.
Watch here: https://tinyurl.com/y2ktufhv.
Register here: https://tinyurl.com/y2ktufhv.
The webinar details step-by-step guidance for moving new or delayed trials to Australia, and Agilex Biolabs' clients
discuss how they made the decision and the benefits, and any challenges.
Agilex Biolabs, the only FDA-inspected lab of its type in the region, is located in Adelaide, South Australia in a
science and biotech specialist hub.
Australia's relatively moderate COVID-19 impact due to rapid localised lockdowns for case clusters, combined with the
world's most attractive 43.5% rebate on clinical trials costs, makes it the ideal destination for re-booting clinical
trials, according to Agilex Biolabs.
Agilex Biolabs and all the early phase units have been open throughout the global COVID-19 pandemic.
CEO Jason Valentine said the key to success was engaging with Agilex Biolabs early.
"By contacting Agilex Biolabs first, for any new trial or trial transition process from another region, we can
facilitate the scoping exercise for sponsors by assessing compatible service providers to ensure a good streamlined fit.
Our 20 years of experience working with all the service providers means we understand the nuances of the Australian
trial landscape and can recommend the right partners to accelerate start up and save on costs. Getting the right fit for
size and experience is vital for success.
This includes everything from CROs, Phase 1 units, sites, Ethics Committees, Government authorities, setting up an
Australian affiliate and legal support. Considerations also include later phase plans and continuity.
Australia is well known as an early phase trials destination and at Agilex Biolabs we have a powerful network of early
phase units, sites and other providers with whom we work regularly.
In addition, our R team need at least 1-2 months to properly develop the assays, and conduct feasibility studies if required."
Biotechs are particularly attracted by Agilex Biolabs' FDA-inspected status, and the 43.5% rebate on clinical trial
spend that applies in Australia.
Agilex Biolabs' world-class bioanalytical facilities have OECD GLP Recognition with NATA (Australian Government OECD GLP
Compliance monitoring authority) and ISO 17025 Accreditation for global recognition.
The company has just expanded its labs by more than 30% to accommodate biotech demand from APAC and the USA. Watch the
New Labs Walkthrough Video Here https://www.agilexbiolabs.com/new-labs-video
Agilex Biolabs specialises in bioanalysis of small molecules and biologics for PK, immunogenicity, biomarkers and
immunological pharmacodynamics assessments utilising LC-MS/MS, immunoassay (Mesoscale, Gurolab, Luminex) and flow
cytometry (BD FACSymphony A3, 20 colour cell analyser).
Agilex also offers pharmacodynamics services that include immunobiology services using the latest state-of-the-art
technology to support immunology, cell biology and mode of action assays, including:ImmunophenotypingReceptor occupancyCytokine release assays (whole blood or PBMC stimulation assays) and cytokine/biomarker profilingPBMC assays and cellular mechanism of action assays (eg: ADCC)
The biolabs has more than 90 staff including 65 dedicated laboratory staff, and annually support more than 80 clinical
trials. This year they will analyse more than 60,000 samples for pharma/biotechs from US, Europe and APAC.
Please Book a Briefing with us before you start your next clinical trial. https://calendly.com/agilexbiolabs/15min